A weight-loss drug is poised for expanded indication
Mar 01, 2019•6 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
The Food and Drug Administration could extend eligibility for Belviq to lower-risk patients, the agency says a popular gout drug raises cardiovascular risk, an AHA statement targets CV risk factors in children, and a class action suit against the American Board of Internal Medicine over MOC gets financial support from doctors.
For the best experience, listen in Metacast app for iOS or Android